Clinical Trial Update: Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating pegylated liposomal doxorubicin plus trastuzumab in HER2-positive metastatic breast cancer is ongoing with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN